SCHEMBL17101341

SCHEMBL17101341

O=C1NC(CC(F)(F)F)C2(CCN(Cc3ccccc3)CC2)O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.45
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
OPRL1 P41146 1/20 0.44
GRIN2D O15399 2/20 0.43
GRIN3B O60391 2/20 0.43
GRIN1 Q05586 2/20 0.43
GRIN2A Q12879 2/20 0.43
GRIN2B Q13224 2/20 0.43
GRIN2C Q14957 2/20 0.43
GRIN3A Q8TCU5 2/20 0.43
CCR5 P51681 4/20 0.43
HSD11B1 P28845 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18075896 0.86 SIGMAR1 (0.48) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL17113644 0.80 OPRM1 (0.50) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL17101486 0.79 OPRL1 (0.46) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL13864847 0.73 OPRL1 (0.48) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL14136159 0.72 OPRL1 (0.47) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL1488906 0.69 GAA (0.50) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL2604320 0.69 TSHR (0.75) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL8364002 0.69 HSD11B1 (0.61) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL17101329 0.69 SIGMAR1 (0.50) SIGMAR1OPRM1OPRD1OPRK1OPRL1
SCHEMBL4462811 0.68 OPRM1 (0.46) SIGMAR1OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202843-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2025-01-21 US disclosed
CN-110903306-B Muscarinic receptor agonists 赫普泰雅治疗有限公司 2022-09-23 CN disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-02-17 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
US-11034704-B2 Muscarinic receptor agonists NXERA PHARMA UK LIMITED (GB) 2021-06-15 US disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3119396-B1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2021-05-05 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed
EP-3271358-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR Heptares Therapeutics Limited (GB) 2018-01-24 EP disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-04-06 US disclosed
EP-3119396-A1 MUSCARINIC RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2017-01-25 EP disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2016147011-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LIMITED (GB) 2016-09-22 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed
WO-2015140559-A1 MUSCARINIC RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096437-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 SIGMAR1 190/4885OPRM1 33/4885OPRD1 86/4885
US-20220048928-A1 MUSCARINIC RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 SIGMAR1 197/4885OPRM1 34/4885OPRD1 87/4885
US-12202843-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 SIGMAR1 197/4885OPRM1 34/4885OPRD1 87/4885
US-11034704-B2 Muscarinic receptor agonists CHRM1, CHRM2, CHRM3 SIGMAR1 197/4885OPRM1 34/4885OPRD1 87/4885
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 SIGMAR1 142/4885OPRM1 59/4885OPRD1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.